Evelo Biosciences, Inc.
Evelo Biosciences, Inc.
Your view on EVLO
Overview
What the company does, where it operates, and who runs it.
About Evelo Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Craig R. Jalbert
- Headquarters
- 620 Memorial Drive, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Craig R. Jalbert
- Headquarters
- 620 Memorial Drive, Cambridge, MA, US
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer.
It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19.
The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Evelo Biosciences, Inc., and the rating behind it. EVLO last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Evelo Biosciences, Inc.. Starting points for Evelo Biosciences, Inc.: EPS -$26.28, beta 0.52 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Evelo Biosciences, Inc.. Evelo Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Evelo Biosciences, Inc.. Trailing twelve-month EPS for Evelo Biosciences, Inc. stands at -$26.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Evelo Biosciences, Inc.. Evelo Biosciences, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Evelo Biosciences, Inc. valued side by side against its closest peers. Evelo Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Evelo Biosciences, Inc., and how their positions are changing. At a $1,898 market value, institutional positions materially move Evelo Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Evelo Biosciences, Inc. executives and directors. Shares of Evelo Biosciences, Inc. have traded between $0.0001 and $0.0025 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Evelo Biosciences, Inc.. Evelo Biosciences, Inc. is a $1,898 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Evelo Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Evelo Biosciences, Inc.. Coverage tracks Evelo Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.